

# Drug Discovery Research Partner of the year - Sweden

Winner: **iNovacia**

## **iNovacia Accelerates Drug Discovery**

iNovacia AB is a leading European contract research organization (CRO) focused on offering world-class preclinical drug-discovery services to Pharmaceutical and Biotech companies as well as Non-Profit Organizations. We build on our strong Pharma heritage and 15 year track-record including several proprietary compounds developed for customers in pre-clinical and clinical development. We have expanded our services to include fully integrated projects from mechanism to candidate drug. The unique integration of biophysical tools, classical state of the art technologies for lead generation and QA/QC systems allows iNovacia to accelerate project time lines (typically from screen to lead series within 8 months) and reach a success rate in preclinical phases that significantly exceeds industry standards. Drug discovery services are provided to meet capacity needs according to highest industry standards as well as fully integrated projects, always planned and executed by senior scientific leaders.

iNovacia takes pride in efficient communication with the customer to ensure that project priorities and quality criteria are met, timely decisions are taken to clear hurdles and targeted deliverables are reached within cost and on time.

A fully electronic and patent compliant documentation system supports the iNovacia drug discovery teams in transferring generated proprietary data and know-how with its full rights to our customers and partners.

Specific strengths of iNovacia include

- \* A wide range of homogeneous assays for biochemical and cellular assays ready to go (e.g. enzymes, GPCR's, TRK's, NR's and Ion channels)
- \* An internationally competitive small molecule screening library characterized by novelty, hit/lead compliance and amenability for rapid expansions
- \* Unique tools for early establishment of SAR to guide medicinal chemistry
- \* Fast turn-around in lead generation integrating medicinal chemistry and HT Analytical chemistry with orthogonal efficacy assays and HT ADME

Based on its long-standing experience from discovering drugs as a center of excellence for lead discovery within Pharmacia and Biovitrum, iNovacia (independent since 2006) knows what it takes to translate important biological discoveries into patent protected candidate drugs.

Contact:

Thomas Olin, CEO, [thomas.olin@inovacia.se](mailto:thomas.olin@inovacia.se)  
 Peter Halkjaer-Knudsen, SVP Business Development, [hape@inovacia.se](mailto:hape@inovacia.se)  
 Martin Norin, CSO, [Martin.Norin@inovacia.se](mailto:Martin.Norin@inovacia.se)  
[www.inovacia.se](http://www.inovacia.se) **ACQ**